2026-04-17T20:41:48Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1986662025-12-05T12:04:41Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT
author
Pignata, Sandro
author
Oza, Amit M.
author
Hall, Geoff
author
Pardo, Beatriz
author
Madry, Radoslaw
author
Cibula, David
author
Klat, Jaroslav
author
Montes Worboys, Ana
author
Glasspool, Rosalind
author
Colombo, Nicoletta
author
Pete, Imre
author
Herrero Ibáñez, Ana
author
Romeo Marín, Margarita
author
Ilieva, Rumyana
author
Timcheva, Constanta
author
Maio, Massimo di
author
Blakeley, Christopher
author
Taylor, Rosie
author
Barnicle, Alan
author
Clamp, Andrew
2023-05-30T08:31:34Z2023-05-30T08:31:34Z2023-05-012023-05-29T12:15:04Z
Background. The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after >= 2 lines of treatment. Methods. Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort.
cc by-nc-nd (c) Pignata, Sandro et al, 2023 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess
Càncer d'ovari
Genètica
Ovarian cancer
Genetics
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion